We Are One Seven LLC Has $248,000 Stock Holdings in GlaxoSmithKline plc (NYSE:GSK)

We Are One Seven LLC boosted its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 13.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,205 shares of the pharmaceutical company’s stock after buying an additional 730 shares during the quarter. We Are One Seven LLC’s holdings in GlaxoSmithKline were worth $248,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Equity Investment Corp lifted its holdings in GlaxoSmithKline by 3.9% during the 1st quarter. Equity Investment Corp now owns 2,776,791 shares of the pharmaceutical company’s stock worth $116,042,000 after buying an additional 105,044 shares in the last quarter. Parametric Portfolio Associates LLC lifted its holdings in GlaxoSmithKline by 4.1% during the 1st quarter. Parametric Portfolio Associates LLC now owns 2,765,250 shares of the pharmaceutical company’s stock worth $115,560,000 after buying an additional 107,713 shares in the last quarter. Brandes Investment Partners LP lifted its holdings in GlaxoSmithKline by 2.1% during the 1st quarter. Brandes Investment Partners LP now owns 2,085,398 shares of the pharmaceutical company’s stock worth $87,149,000 after buying an additional 42,656 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of GlaxoSmithKline by 5.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,769,859 shares of the pharmaceutical company’s stock valued at $67,626,000 after acquiring an additional 88,148 shares during the last quarter. Finally, Kahn Brothers Group Inc. DE raised its position in shares of GlaxoSmithKline by 1.2% during the 1st quarter. Kahn Brothers Group Inc. DE now owns 1,276,550 shares of the pharmaceutical company’s stock valued at $53,347,000 after acquiring an additional 15,610 shares during the last quarter. 11.25% of the stock is currently owned by hedge funds and other institutional investors.

Shares of GlaxoSmithKline stock traded up $0.27 on Thursday, hitting $41.55. 60,916 shares of the company’s stock traded hands, compared to its average volume of 2,413,201. The firm has a 50-day moving average price of $40.79. The company has a market cap of $102.05 billion, a PE ratio of 13.14, a PEG ratio of 2.20 and a beta of 0.74. GlaxoSmithKline plc has a one year low of $36.41 and a one year high of $42.47. The company has a quick ratio of 0.48, a current ratio of 0.71 and a debt-to-equity ratio of 7.86.

GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 24th. The pharmaceutical company reported $0.78 EPS for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. The business had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Research analysts expect that GlaxoSmithKline plc will post 2.91 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, July 11th. Investors of record on Friday, May 17th were given a $0.4953 dividend. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.77%. The ex-dividend date was Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio is currently 58.86%.

In other news, Director Plc Glaxosmithkline acquired 385,714 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $5,399,996.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 10.00% of the stock is owned by corporate insiders.

GSK has been the subject of several recent research reports. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Thursday, April 25th. Morgan Stanley reiterated an “underweight” rating on shares of GlaxoSmithKline in a research report on Monday, June 17th. Finally, Cowen reiterated a “hold” rating and set a $45.00 target price on shares of GlaxoSmithKline in a research report on Monday, June 10th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and three have issued a buy rating to the stock. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus price target of $42.66.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: Buy-Side Analysts

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.